Oct 22, 2026 08:00AM
Oct 22, 2026 08:00AM
Sep 30, 2026 08:00AM
Sep 10, 2026 08:05AM
Sep 8, 2026 08:00AM
Aug 27, 2026 08:00AM
Aug 27, 2026 08:00AM Verrica Pharmaceuticals Announces Completion of Enrollment in First Pivotal Phase 3 Trial (COVE-2) Evaluating YCANTH® for the Treatment of Common Warts, with Topline Data Expected Q1 2027
Aug 6, 2026 04:05PM
Aug 6, 2026 04:01PM
Aug 6, 2026 04:01PM
Jul 30, 2026 08:00AM
Jul 21, 2026 08:00AM
Jul 21, 2026 08:00AM
Jun 22, 2026 08:05AM Verrica doses first U.S. patient in COVE-3 trial for common warts
Jun 22, 2026 08:05AM
May 28, 2026 08:05AM
May 13, 2026 08:00AM
May 12, 2026 04:01PM
May 5, 2026 04:06PM
May 5, 2026 04:05PM
May 5, 2026 08:00AM Verrica Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 12, 2026
Apr 9, 2026 04:05PM
Apr 6, 2026 08:00AM
Mar 11, 2026 08:00AM
Mar 5, 2026 08:00AM
Feb 23, 2026 08:00AM
Feb 12, 2026 08:00AM
Feb 12, 2026 08:00AM Verrica Pharmaceuticals Appoints Chris Chapman as Chief Commercial Officer
Feb 9, 2026 08:03AM
Feb 9, 2026 08:00AM
Jan 7, 2026 11:34AM
Jan 7, 2026 08:00AM
Jan 7, 2026 08:00AM
Nov 24, 2025 08:00AM
Nov 24, 2025 08:00AM Verrica Pharmaceuticals Announces Private Placement Financing of $50 Million to Retire Debt and Extend Cash Runway
Nov 14, 2025 04:05PM
Nov 10, 2025 08:00AM
Nov 10, 2025 08:00AM
Nov 5, 2025 06:36AM
Oct 20, 2025 04:06PM
Oct 20, 2025 04:05PM
Oct 7, 2025 04:05PM Verrica Pharmaceuticals to present VP-315 data at cancer meeting
Oct 7, 2025 04:05PM
Sep 19, 2025 08:02AM
Sep 19, 2025 08:00AM
Sep 2, 2025 07:00AM
Aug 12, 2025 04:01PM
Aug 12, 2025 04:01PM
Aug 6, 2025 07:00AM Verrica Pharmaceuticals to Report Second Quarter 2025 Financial Results and Provide a Corporate Update on August 12, 2025
Jul 9, 2025 07:02AM

335,228 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All